Brokers Issue Forecasts for Aura Biosciences, Inc.’s Q3 2024 Earnings (NASDAQ:AURA)

Aura Biosciences, Inc. (NASDAQ:AURA) – Lifesci Capital issued their Q3 2024 earnings per share estimates for shares of Aura Biosciences in a report released on Monday, September 9th. Lifesci Capital analyst A. Dhankher forecasts that the company will earn ($0.42) per share for the quarter. Lifesci Capital currently has a “Strong-Buy” rating on the stock. The consensus estimate for Aura Biosciences’ current full-year earnings is ($1.70) per share. Lifesci Capital also issued estimates for Aura Biosciences’ Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.65) EPS and FY2025 earnings at ($2.52) EPS.

A number of other analysts have also commented on AURA. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research report on Friday. JMP Securities lifted their price target on shares of Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday.

Aura Biosciences Stock Performance

Shares of AURA opened at $10.07 on Thursday. The stock has a fifty day moving average price of $8.52 and a two-hundred day moving average price of $7.88. The company has a market cap of $499.57 million, a price-to-earnings ratio of -5.41 and a beta of 0.35. Aura Biosciences has a 52-week low of $5.99 and a 52-week high of $12.35.

Aura Biosciences (NASDAQ:AURA) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.04.

Hedge Funds Weigh In On Aura Biosciences

A number of large investors have recently made changes to their positions in the company. American Century Companies Inc. acquired a new stake in shares of Aura Biosciences during the 2nd quarter valued at $119,000. Trexquant Investment LP boosted its holdings in shares of Aura Biosciences by 64.5% during the 4th quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after acquiring an additional 6,809 shares in the last quarter. American International Group Inc. boosted its holdings in shares of Aura Biosciences by 27.4% during the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock valued at $138,000 after acquiring an additional 3,782 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Aura Biosciences during the 1st quarter valued at $144,000. Finally, TBH Global Asset Management LLC boosted its holdings in shares of Aura Biosciences by 82.3% during the 4th quarter. TBH Global Asset Management LLC now owns 60,322 shares of the company’s stock valued at $534,000 after acquiring an additional 27,225 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.